New Frontiers in Pharma R&D Investment

Given their diminishing R&D productivity, pharma companies have externalized more R&D in order to increase the number of drug projects and thus the chances of getting a major new product onto the market. But by and large, this externalization has used fairly traditional models, like product licensing, and hasn't fundamentally improved R&D's economics. Instead, these investment programs must increase the number of drug assets to which a pharmaceutical company has access - but without increasing to the same degree the capital or resource investment required to access them. Thus, a growing number of companies have begun to pursue new investment ideas that recognize that much of the value comes from having preferential access to the information needed to decide whether to exercise rights to programs - rather than day-to-day operational responsibilities. This article provides a framework for deciding among innovative models, and in particular, how to apply multiple approaches across an entire portfolio.

by Troy Norris, Navjot Singh, Tony Tramontin, Eric David, and Amit Mehta

It's no secret that the biopharma industry has been grappling with diminishing R&D productivity. R&D investment more than doubled over the last decade, while new molecular entity (NME) approvals plummeted....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.